AR097009A1 - Compuestos isoindolina o isoquinolina, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para diferentes tipos de cáncer - Google Patents
Compuestos isoindolina o isoquinolina, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para diferentes tipos de cáncerInfo
- Publication number
- AR097009A1 AR097009A1 ARP140102713A ARP140102713A AR097009A1 AR 097009 A1 AR097009 A1 AR 097009A1 AR P140102713 A ARP140102713 A AR P140102713A AR P140102713 A ARP140102713 A AR P140102713A AR 097009 A1 AR097009 A1 AR 097009A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- branched
- linear
- optionally substituted
- alkyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000002950 monocyclic group Chemical group 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000003003 spiro group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000006684 polyhaloalkyl group Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Medicamentos contra el cáncer. Reivindicación 1: Compuesto de fórmula (1), en la que: Het representa un grupo heteroarilo; T representa un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente con uno a tres átomos de halógeno, un grupo alquil C₁₋₄-NR¹R², o un grupo alquil C₁₋₄-OR⁶; R¹ y R² representan independientemente el uno del otro un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado, o R¹ y R² forman con el átomo de nitrógeno al que están unidos un grupo heterocicloalquilo; R³ representa un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un grupo cicloalquilo, un grupo cicloalquil C₃₋₁₀-alquilo C₁₋₆ en el que el grupo alquilo puede ser lineal o ramificado, un grupo heterocicloalquilo, un grupo arilo o un grupo heteroarilo, entendiéndose que uno o más átomos de carbono de los grupos definidos aquí anteriormente, o átomos de carbono de sus posibles sustituyentes, puede(n) estar deuterado(s); R⁴ representa un grupo arilo, heteroarilo, cicloalquilo o alquilo C₁₋₆ lineal o ramificado, entendiéndose que uno o más átomos de carbono de los grupos definidos aquí anteriormente, o átomos de carbono de sus posibles sustituyentes, puede(n) estar deuterado(s); R⁵ representa un átomo de hidrógeno o un átomo de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, o un grupo alcoxi C₁₋₆ lineal o ramificado; R⁶ representa un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado; R⁷ representa un grupo seleccionado de R⁷, R⁷-CO-, R⁷-O-CO-, NR⁷R⁷-CO-, R⁷-SO₂-, R⁷NR⁷-SO₂- en los que R⁷ y R⁷ representan independientemente el uno del otro un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado o un grupo alquinilo C₂₋₆ lineal o ramificado, un cicloalquilo, un heterocicloalquilo, un grupo arilo o un heteroarilo; R⁸ y R⁹ representan, independientemente el uno del otro, un grupo oxo o un átomo de halógeno; p y p son, independientemente el uno del otro, números enteros iguales a 0, 1, 2, 3 ó 4; q y q son, independientemente el uno del otro, números enteros iguales a 1, 2 ó 3; entendiéndose que cuando el compuesto de fórmula (1) contiene un grupo hidroxi, este último grupo puede estar sustituido opcionalmente con uno de los grupos siguientes: -PO(OM)(OM), -PO(OM)(O⁻M₁⁺), -PO(O⁻M₁⁺)(O⁻M₂⁺), -PO(O⁻)(O⁻)M₃²⁺, -PO(OM)(O[CH₂CH₂O]ₙCH₃), o -PO(O⁻M₁⁺)(O[CH₂CH₂O]ₙCH₃), en los que M y M representan independientemente el uno del otro un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un cicloalquilo o un heterocicloalquilo, estando los dos compuestos por de 5 a 6 miembros en el anillo, mientras que M₁⁺ y M₂⁺ representan independientemente el uno del otro un catión monovalente farmacéuticamente aceptable, M₃²⁺ representa un catión divalente farmacéuticamente aceptable y n es un número entero comprendido entre 1 y 5; entendiéndose también que: arilo significa un grupo fenilo, naftilo, bifenilo o indenilo; heteroarilo significa cualquier grupo mono o bicíclico compuesto por de 5 a 10 miembros en el anillo, que tiene al menos una parte aromática y que contiene de 1 a 4 heteroátomos seleccionados de oxígeno, azufre y nitrógeno (incluyendo los nitrógenos cuaternarios); cicloalquilo significa cualquier grupo carbocíclico no aromático mono o bicíclico que contiene de 3 a 10 miembros en el anillo, que puede incluir sistemas de anillo fusionados, con puente o espiro; heterocicloalquilo significa cualquier grupo carbocíclico no aromático mono o bicíclico, compuesto por de 3 a 10 miembros en el anillo, y que contiene de uno a 3 heteroátomos seleccionados de oxígeno, azufre, SO, SO₂ y nitrógeno; entendiéndose que el grupo bicíclico puede ser de tipo fusionado o espiro, siendo posible para los grupos arilo, heteroarilo, cicloalquilo y heterocicloalquilo así definidos y los alquilo, alquenilo, alquinilo, alcoxi, estar sustituidos con de 1 a 3 grupos seleccionados de: alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente; grupo alquenilo C₂₋₆ lineal o ramificado sustituido opcionalmente; grupo alquinilo C₂₋₆ lineal o ramificado sustituido opcionalmente; espiro C₃₋₆; alcoxi C₁₋₆ lineal o ramificado sustituido opcionalmente; alquil C₁₋₆-S-; hidroxilo; oxo (o N-óxido cuando sea apropiado); nitro; ciano; -COOR; -OCOR; -NRR; RCONR-; NRRCO-; polihaloalquilo C₁₋₆ lineal o ramificado; trifluorometoxi; alquil C₁₋₆sulfonilo; halógeno; arilo sustituido opcionalmente; heteroarilo sustituido opcionalmente; ariloxi sustituido opcionalmente; ariltio sustituido opcionalmente; cicloalquilo sustituido opcionalmente o heterocicloalquilo sustituido opcionalmente, entendiéndose que R y R representan, independientemente el uno del otro, un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente o un grupo arilo; sus enantiómeros y diastereoisómeros, y sales de adición de éstos con un ácido o a una base farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357276A FR3008977A1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097009A1 true AR097009A1 (es) | 2016-02-10 |
Family
ID=49911606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102713A AR097009A1 (es) | 2013-07-23 | 2014-07-22 | Compuestos isoindolina o isoquinolina, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para diferentes tipos de cáncer |
Country Status (49)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN109311874B (zh) | 2016-04-20 | 2021-07-30 | 百时美施贵宝公司 | 经取代的二环杂环化合物 |
| EP3814338A1 (en) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| CN112010796B (zh) * | 2020-09-17 | 2022-04-22 | 浙江大学 | 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法 |
| WO2023161317A1 (en) | 2022-02-24 | 2023-08-31 | Les Laboratoires Servier | 5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-y l]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents |
| TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| WO2004096774A1 (en) | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
| US20050070570A1 (en) | 2003-06-18 | 2005-03-31 | 4Sc Ag | Novel potassium channels modulators |
| CA2577752A1 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| ZA200702257B (en) * | 2004-08-20 | 2009-06-24 | Univ Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| JP2008530174A (ja) * | 2005-02-15 | 2008-08-07 | ノボ ノルディスク アクティーゼルスカブ | ３，４−ジヒドロ−１ｈ−イソキノリン−２−カルボン酸５−アミノピリジン−２−イルエステル |
| BRPI0810365A2 (pt) | 2007-04-16 | 2014-10-29 | Abbott Lab | Inibidores de mlc-1 de indol 7-substituído |
| CN102007101A (zh) | 2007-11-30 | 2011-04-06 | 生物区科学管理控股有限公司 | 作为抗菌剂的四氢-异喹啉ppat抑制剂 |
| NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| WO2009102463A2 (en) | 2008-02-14 | 2009-08-20 | Connor Reynolds | Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same |
| WO2012162365A1 (en) * | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| MX2014007730A (es) * | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| WO2013100890A1 (en) | 2011-12-27 | 2013-07-04 | Intel Corporation | Methods and systems to control power gates during an active state of a gated domain based on load conditions of the gated domain |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357276A patent/FR3008977A1/fr not_active Withdrawn
-
2014
- 2014-07-13 JO JOP/2014/0223A patent/JO3457B1/ar active
- 2014-07-15 UY UY0001035664A patent/UY35664A/es active IP Right Grant
- 2014-07-22 US US14/905,985 patent/US9809574B2/en active Active
- 2014-07-22 ES ES14741648T patent/ES2711371T3/es active Active
- 2014-07-22 DK DK14741648.1T patent/DK3024826T3/en active
- 2014-07-22 CN CN201480042422.3A patent/CN105431422B/zh active Active
- 2014-07-22 HU HUE14741648A patent/HUE041443T2/hu unknown
- 2014-07-22 EA EA201600122A patent/EA032301B1/ru unknown
- 2014-07-22 RS RS20190150A patent/RS58344B1/sr unknown
- 2014-07-22 PT PT14741648T patent/PT3024826T/pt unknown
- 2014-07-22 LT LTEP14741648.1T patent/LT3024826T/lt unknown
- 2014-07-22 WO PCT/EP2014/065764 patent/WO2015011164A1/en active Application Filing
- 2014-07-22 KR KR1020167004570A patent/KR102008431B1/ko active IP Right Grant
- 2014-07-22 SI SI201431038T patent/SI3024826T1/sl unknown
- 2014-07-22 JP JP2016528512A patent/JP6395829B2/ja active Active
- 2014-07-22 UA UAA201601395A patent/UA117490C2/uk unknown
- 2014-07-22 CU CUP2016000010A patent/CU24352B1/es unknown
- 2014-07-22 TR TR2018/19155T patent/TR201819155T4/tr unknown
- 2014-07-22 MD MDA20160018A patent/MD4793C1/ro active IP Right Grant
- 2014-07-22 AP AP2016008989A patent/AP2016008989A0/xx unknown
- 2014-07-22 PE PE2016000023A patent/PE20160241A1/es unknown
- 2014-07-22 MX MX2016000904A patent/MX365373B/es active IP Right Grant
- 2014-07-22 ME MEP-2019-35A patent/ME03346B/me unknown
- 2014-07-22 CA CA2919572A patent/CA2919572C/en active Active
- 2014-07-22 GE GEAP201414063A patent/GEP20207070B/en unknown
- 2014-07-22 RU RU2016106003A patent/RU2689305C2/ru active
- 2014-07-22 MA MA38801A patent/MA38801B1/fr unknown
- 2014-07-22 SG SG11201600205XA patent/SG11201600205XA/en unknown
- 2014-07-22 BR BR112016001080-9A patent/BR112016001080B1/pt active IP Right Grant
- 2014-07-22 PL PL14741648T patent/PL3024826T3/pl unknown
- 2014-07-22 AR ARP140102713A patent/AR097009A1/es active IP Right Grant
- 2014-07-22 TW TW103125161A patent/TWI560184B/zh active
- 2014-07-22 TN TN2016000003A patent/TN2016000003A1/en unknown
- 2014-07-22 EP EP14741648.1A patent/EP3024826B1/en active Active
- 2014-07-22 MY MYPI2016700106A patent/MY193619A/en unknown
- 2014-07-22 NZ NZ716155A patent/NZ716155A/en unknown
- 2014-07-22 AU AU2014295101A patent/AU2014295101B2/en active Active
- 2014-07-22 CN CN201811358313.9A patent/CN109456324B/zh active Active
-
2016
- 2016-01-03 IL IL243449A patent/IL243449A0/en active IP Right Grant
- 2016-01-06 PH PH12016500034A patent/PH12016500034B1/en unknown
- 2016-01-11 ZA ZA2016/00198A patent/ZA201600198B/en unknown
- 2016-01-11 DO DO2016000009A patent/DOP2016000009A/es unknown
- 2016-01-15 CR CR20160030A patent/CR20160030A/es unknown
- 2016-01-20 CL CL2016000148A patent/CL2016000148A1/es unknown
- 2016-01-21 NI NI201600016A patent/NI201600016A/es unknown
- 2016-01-21 SA SA516370439A patent/SA516370439B1/ar unknown
- 2016-06-13 HK HK16106761.6A patent/HK1218754A1/zh unknown
- 2016-09-21 HK HK16111083.7A patent/HK1222856A1/zh unknown
-
2017
- 2017-09-14 US US15/704,330 patent/US10689364B2/en active Active
-
2019
- 2019-02-11 CY CY20191100175T patent/CY1121247T1/el unknown
- 2019-02-12 HR HRP20190277TT patent/HRP20190277T1/hr unknown
-
2020
- 2020-05-04 US US16/865,799 patent/US11028070B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105103A1 (es) | Derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR105102A1 (es) | Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR097009A1 (es) | Compuestos isoindolina o isoquinolina, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para diferentes tipos de cáncer | |
| AR098906A1 (es) | Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR105101A1 (es) | Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR108706A1 (es) | Derivados piperidinilo, un proceso para su preparación, y composiciones farmacéuticas que los contienen | |
| AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR102799A1 (es) | Profármacos de agonistas fenólicos de trpv1 | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR098337A1 (es) | Triazolopirazina | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR088474A1 (es) | Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |